Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
7%
3D Co-culture
7%
Breast Cancer
74%
Breast Cancer Patients
28%
Breast Cancer Survivors
7%
Breast Cancer Treatment
12%
Cancer Cells
9%
Cancer Control
9%
Capecitabine
14%
Cell-based
14%
Chemotherapy
14%
Clinical Methods
7%
Clinical Practice
7%
Cytotoxic T Lymphocytes
30%
Disease-free Survival
19%
Docetaxel
10%
Early Breast Cancer
27%
Endocrine Therapy
9%
Estrogen Receptor-positive Breast Cancer
14%
Global Cancer
7%
Hazard Ratio
8%
HLA-DR
23%
HLA-DR Expression
16%
Human Epidermal Growth Factor Receptor 2 (HER2)
21%
Human Microbiota
14%
Hypoxic Response
7%
Immune Cells
8%
Invasive Disease
7%
Lewis A
8%
Low-density Neutrophils
14%
Metastatic Breast Cancer
18%
Metastatic Triple-negative Breast Cancer
7%
Neoadjuvant Chemotherapy
7%
Neoadjuvant Systemic Therapy
7%
Neutrophils
9%
Notch Signaling
9%
Overall Survival
8%
Pathological Complete Response
7%
Phase II Trial
14%
Resistance to Targeted Therapy
7%
Response to Neoadjuvant Chemotherapy
14%
Sexual Function Questionnaire
7%
Sialyl Lewis X
9%
Sunitinib
7%
Therapeutic Potential
14%
Trastuzumab
28%
Triple-negative Breast Cancer
16%
Tucatinib
7%
Tumor
11%
Tumor Tissue
9%
Pharmacology, Toxicology and Pharmaceutical Science
Anthracycline
7%
Biological Marker
7%
Breast Cancer
100%
Capecitabine
14%
Cetuximab
7%
Chemotherapy
32%
Cisplatin
7%
Clinical Trial
7%
Disease Free Survival
14%
Diseases
19%
Docetaxel
9%
Drug Development
7%
Endocrine Therapy
8%
Epidermal Growth Factor Receptor
8%
Epidermal Growth Factor Receptor 2
14%
Estrogen Receptor
9%
Estrogen Receptor Positive Breast Cancer
11%
Fluorodeoxyglucose F 18
7%
Gamma Urogastrone
16%
Immunotherapy
7%
Malignant Neoplasm
26%
Metastatic Breast Cancer
17%
Microflora
14%
Monoclonal Antibody
10%
Neoplasm
16%
Overall Survival
8%
Phase III Trials
7%
Polyethylene Terephthalate
7%
Progression Free Survival
7%
Receptor
5%
Sunitinib
7%
Trastuzumab
18%
Triple Negative Breast Cancer
7%
Tucatinib
7%
Tumor Growth
5%
Medicine and Dentistry
Biological Marker
9%
Breast Cancer
98%
Cancer
6%
Cancer Cell
7%
Cancer Control
7%
Cancer Therapy
6%
Carcinosarcoma
7%
Clinical Trial
12%
Cytotoxic T-Cell
28%
Disease Free Survival
9%
Diseases
19%
Endothelial Leukocyte Adhesion Molecule 1
7%
Epidermal Growth Factor Receptor 2
9%
Estrogen Receptor
7%
Fluorodeoxyglucose F 18
7%
Gamma Urogastrone
8%
Health Care Cost
7%
Hormone Therapy
7%
Hypoxic Response
7%
Immunoglobulin
6%
Immunotherapy
7%
Locally Advanced Breast Cancer
7%
Lymphocyte
7%
Malignant Neoplasm
19%
Metastatic Breast Cancer
10%
Neoadjuvant Chemotherapy
20%
Neoplasm
17%
Neutrophil
7%
Next Generation Sequencing
7%
Personalized Medicine
7%
Polyethylene Terephthalate
7%
Sunitinib
7%
Systemic Therapy
9%
T Cell
15%
Targeted Therapy
10%
Trastuzumab
10%
Triple Negative Breast Cancer
8%
Tumor
15%